Eric Patzer - 04 May 2023 Form 4 Insider Report for Aridis Pharmaceuticals, Inc.

Role: Executive Chairman, Director
Signature: /s/ Eric Patzer
Issuer symbol: N/A
Transactions as of: 04 May 2023
Net transactions value: $0
Form type: 4
Filing time: 15 Jun 2023, 17:16:00 UTC
Previous filing: 07 Dec 2022
Next filing: 19 Sep 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ARDS	Common Stock	Options Exercise		+12,000	+1.7%		714,132	05 Jun 2023	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ARDS	Stock Options	Award	$0	+30,000	+26%	$0.000000	146,862	04 May 2023	Common Stock	30,000	$0.1600	Direct	F1
transaction	ARDS	Restricted Stock Units	Options Exercise		-12,000	-50%		12,000	05 Jun 2023	Common Stock	12,000		Direct	F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	50% of the options vest on the three month anniversary of the date of grant and the remainder vest on the six month anniversary of the date of grant.
F2	Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F3	12,000 shares of Common Stock vested on June 5, 2023 and 12,000 will vest on 12/5/2023. In the event that the Reporting Person's employment is terminated without cause by the Issuer, the RSUs will immediately vest.